Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)
NCT ID: NCT01629927
Last Updated: 2012-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2012-03-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation
NCT01386775
Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype
NCT01398397
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia
NCT01108770
Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia
NCT01109290
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A
NCT01293565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HED-affected males
Male subjects affected by HED
No interventions assigned to this group
Male controls
Male subjects not affected by HED
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Attending the 2012 Spanish Association for those Affected by Ectodermal Dysplasia Annual Reunion;
* One year of age or greater;
* Conform to one of the following requirements for providing informed consent/assent:
* If more than 18 years of age, subjects must provide signed informed consent;
* If less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;
* If the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.
* Can provide documentation of genetic testing results positive for an EDA gene mutation /deletion;
* As described in Section 3.2 above, subjects must meet one of the following criteria:
* Documented diagnosis of XLHED confirmed via genetic testing;
* Unaffected male controls.
Exclusion Criteria
* Presence of pacemakers;
* Subjects who are not able or are not willing to comply with the procedures of this protocol;
* Subjects with any major medical problem that will prevent them from participating in this study.
1 Year
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Edimer Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Encarna Navarro, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Virgen de la Arrixaca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Rare Diseases
Burgos, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECP-012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.